Event JSON
{
"id": "1f7340b7fa18307bfc070f2dbd94fb4611eb2581b3615aab13d370ea409939db",
"pubkey": "9824e73f2d2ada49816d43b8cd686b9f11b939cba1b1ec5ba9cc7c96e6265a80",
"created_at": 1734639556,
"kind": 1,
"tags": [
[
"r",
"https://abcnews.go.com/Health/wireStory/fda-knockoff-versions-lilly-obesity-drug-off-market-116959863"
],
[
"subject",
"FDA: Knockoff versions of Lilly obesity drug must come off the market"
],
[
"published_at",
"1734639367"
],
[
"image",
"https://s.abcnews.com/images/Health/wirestory_13d18b0e3e74a7f7355521bf8e38cb5b_4x3_384.jpg"
],
[
"p",
"9824e73f2d2ada49816d43b8cd686b9f11b939cba1b1ec5ba9cc7c96e6265a80",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://s.abcnews.com/images/Health/wirestory_13d18b0e3e74a7f7355521bf8e38cb5b_4x3_384.jpg"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"The Food and Drug Administration has announced that a nationwide shortage of Eli Lilly's Zepbound and Mounjaro has been resolved, eliminating the need for copycat versions of the drugs. The decision is a win for Lilly, which had been pressing the FDA to take the step for months. The FDA permits compounded versions of brand name drugs when they are in shortage, but the shift back to Lilly's medications could improve safety for consumers. The agency has limited oversight of compounding pharmacies, which are primarily overseen by state authorities."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqnqjww0ed9tdynqtdgwuv66rtnugmjwwt5xc7ckafe37fde3xt2qq4hznwr\nhttps://s.abcnews.com/images/Health/wirestory_13d18b0e3e74a7f7355521bf8e38cb5b_4x3_384.jpg\nThe federal government is phasing out off-brand copies of two blockbuster drugs used to treat obesity and diabetes\nhttps://abcnews.go.com/Health/wireStory/fda-knockoff-versions-lilly-obesity-drug-off-market-116959863",
"sig": "9d2acf7e626073a4bf246f5610086a0aa5083cb32c7b5bb24d116ad89ed3505e6d4c32c00f3a393ffc73e5d81be7b7e47da6945a0e3c05389ded8ee514668f2e"
}
